Ubs Oconnor LLC C4 Therapeutics, Inc. Transaction History
Ubs Oconnor LLC
- $1.51 Billion
- Q4 2024
A detailed history of Ubs Oconnor LLC transactions in C4 Therapeutics, Inc. stock. As of the latest transaction made, Ubs Oconnor LLC holds 137,360 shares of CCCC stock, worth $296,697. This represents 0.03% of its overall portfolio holdings.
Number of Shares
137,360Holding current value
$296,697% of portfolio
0.03%Shares
2 transactions
Others Institutions Holding CCCC
# of Institutions
126Shares Held
63MCall Options Held
651KPut Options Held
115K-
Soleus Capital Management, L.P. Greenwich, CT6.98MShares$15.1 Million1.75% of portfolio
-
Lynx1 Capital Management LP San Juan, PR6.85MShares$14.8 Million9.58% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT6.07MShares$13.1 Million0.11% of portfolio
-
Ra Capital Management, L.P. Boston, MA4.88MShares$10.5 Million0.28% of portfolio
-
Black Rock Inc. New York, NY4.55MShares$9.83 Million0.0% of portfolio
About C4 Therapeutics, Inc.
- Ticker CCCC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,913,800
- Market Cap $106M
- Description
- C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...